Innate Pharma specializes in immuno-oncology and has a diverse pipeline of potential first-in-class clinical and preclinical candidates. The company's expertise in natural killer cell biology, tumor microenvironment, and antibody engineering has led to major collaborations with industry leaders. Innate Pharma is listed on Euronext Paris and Nasdaq and generates revenue through research and licensing agreements with pharmaceutical companies.